Phase I study of ontuxizumab, a humanized monoclonal antibody (mAb) recognizing endosialin in Japanese patients (pts) with hepatocellular carcinoma (HCC).

被引：0
|
作者：
Ikeda, Masafumi
Aramaki, Takeshi
Inaba, Yoshitaka
Nakai, Kenya
Doi, Toshihiko
Okusaka, Takuji
机构：
[1] Natl Canc Ctr Hosp East, Chiba, Japan
[2] Shizuoka Canc Ctr, Shizuoka, Japan
[3] Aichi Canc Ctr Hosp, Dept Intervent & Diagnost Radiol, Nagoya, Aichi 464, Japan
[4] Eisai & Co Ltd, Tokyo, Japan
[5] Natl Canc Ctr, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.2521
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2521
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study.
    Martell, Robert E.
    Puzanov, Igor
    Ma, Wen Wee
    Santoro, Armando
    Dy, Grace K.
    Goff, Laura Williams
    Fetterly, Gerald J.
    Michael, Shaunita A.
    Means-Powell, Julie Ann
    Chai, Feng
    Lamar, Maria
    Simonelli, Matteo
    Chiang, Wendy M.
    Jarboe, Jamie
    Schwartz, Brian E.
    Adjei, Alex A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC).
    Evans, T. R. Jeffry
    Basu, Bristi
    Hubner, Richard
    Ma, Yuk Ting
    Meyer, Tim
    Palmer, Daniel H.
    Pinato, David J. James
    Plummer, Elizabeth Ruth
    Ross, Paul J.
    Samson, Adel
    Sarker, Debashis
    Kendall, Timothy
    Bellamy, Christopher
    Reeves, Helen L.
    Thomson, Fiona
    Lawless, Claire A.
    Stobo, Jamie
    Sansom, Owen J.
    Mann, Derek A.
    Bird, Thomas G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS631 - TPS631
  • [43] Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment
    Okusaka, Takuji
    Otsuka, Taiga
    Ueno, Hideki
    Mitsunaga, Shuichi
    Sugimoto, Rie
    Muro, Kei
    Saito, Isao
    Tadayasu, Yusuke
    Inoue, Kohei
    Loembe, Arsene-Bienvenu
    Ikeda, Masafumi
    CANCER SCIENCE, 2016, 107 (12) : 1791 - 1799
  • [44] A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors
    Sasaki, Yasutsuna
    Miwa, Keisuke
    Yamashita, Keishi
    Sunakawa, Yu
    Shimada, Ken
    Ishida, Hiroo
    Hasegawa, Kosei
    Fujiwara, Keiichi
    Kodaira, Makoto
    Fujiwara, Yasuhiro
    Namiki, Masayuki
    Matsuda, Minami
    Takeuchi, Yutaka
    Katsumata, Noriyuki
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (02) : 332 - 340
  • [45] Phase I/II study of S-1 in patients (pts) with advanced hepatocellular carcinoma (HCC): Results of phase I part - Correlation between pharmacokinetics (PK) and hepatic dysfunction
    Furuse, J.
    Okusaka, T.
    Ishii, H.
    Nakachi, K.
    Suzuki, E.
    Shimizu, S.
    Ueno, H.
    Ikeda, M.
    Morizane, C.
    Ogura, T.
    EJC SUPPLEMENTS, 2007, 5 (04): : 275 - 275
  • [46] A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors
    Yasutsuna Sasaki
    Keisuke Miwa
    Keishi Yamashita
    Yu Sunakawa
    Ken Shimada
    Hiroo Ishida
    Kosei Hasegawa
    Keiichi Fujiwara
    Makoto Kodaira
    Yasuhiro Fujiwara
    Masayuki Namiki
    Minami Matsuda
    Yutaka Takeuchi
    Noriyuki Katsumata
    Investigational New Drugs, 2015, 33 : 332 - 340
  • [47] Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma
    Takeda, Masayuki
    Ohe, Yuichiro
    Horinouchi, Hidehito
    Hida, Toyoaki
    Shimizu, Junichi
    Seto, Takashi
    Nosaki, Kaname
    Kishimoto, Takumi
    Miyashita, Itaru
    Yamada, Masayuki
    Kaneko, Yutaro
    Morimoto, Chikao
    Nakagawa, Kazuhiko
    LUNG CANCER, 2019, 137 : 64 - 70
  • [48] A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC)
    Yopp, Adam Charles
    Singal, Amit G.
    Arriaga, Yull Edwin
    Verma, Udit N.
    Shan, Joseph
    Kallinteris, Nikoletta L.
    Beg, Muhammad Shaalan
    Mansour, John C.
    Zhu, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)
    Ryoo, B-Y.
    Ren, Z.
    Kim, T-Y.
    Pan, H.
    Rau, K-M.
    Choi, H. J.
    Park, J-W.
    Kim, J. H.
    Yen, C-J.
    Kim, B-H.
    Zhou, D.
    Straub, J.
    Zhao, C.
    Qin, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [50] Phase II trial of sorafenib (S) and capecitabine (C) for hepatocellular carcinoma (HCC) in cirrhotic patients (pts).
    Rojas-Hernandez, Cristhiam Mauricio
    Patt, Yehuda Z.
    Fekrazad, M. Houman
    Steinberg, Kim A.
    Roach, Mary
    Lee, Fa-Chyi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345